New insider activity at Ocular Therapeutix ( (OCUL) ) has taken place on October 10, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Todd Anderman, the Chief Legal Officer of Ocular Therapeutix, has recently sold 11,132 shares of the company’s stock, amounting to a total transaction value of $137,368.
Recent Updates on OCUL stock
Ocular Therapeutix has seen multiple analysts raise their price targets due to strategic advancements and promising clinical trials, particularly in diabetic retinopathy and wet age-related macular degeneration (AMD). H.C. Wainwright increased their target based on potential sales of Axpaxli in non-proliferative diabetic retinopathy. Piper Sandler’s confidence in the company’s Phase 3 programs for wet AMD and NPDR led to a higher sales estimate for AXPAXLI. Baird updated their model following the company’s investor day, while Citizens JMP attributed their target increase to new details on a derisked pivotal program in NPDR. Additionally, the company announced a significant stock offering to fund clinical trials and operational growth, which is expected to extend their cash runway into 2028.
Spark’s Take on OCUL Stock
According to Spark, TipRanks’ AI Analyst, OCUL is a Neutral.
Ocular Therapeutix’s overall stock score is primarily impacted by its financial performance, which shows significant challenges with declining revenues and persistent losses. The technical analysis suggests some short-term weakness, while the valuation is unattractive due to negative earnings. However, the earnings call provided a positive outlook with advancements in clinical trials and a strong cash position, which partially offsets the financial concerns.
To see Spark’s full report on OCUL stock, click here.
More about Ocular Therapeutix
YTD Price Performance: 36.61%
Average Trading Volume: 2,597,948
Technical Sentiment Signal: Buy
Current Market Cap: $2.52B